Israel Englander’s Windtree Therapeutics WINT Stock Holding History

Israel Englander’s Portfolio WINT Stock Details WINT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$14K	–	6924
2022 Q4	$14K	Buy	+2	New	+$17.8K	﹤0.01%	6131
2022 Q3	–	Sell	-2	Closed	-$35.7K	–	6812
2022 Q2	$33K	Buy	+2	New	+$59K	﹤0.01%	6326
2022 Q1	–	Hold	0	–	–	–	6660
2021 Q4	–	Hold	0	–	–	–	6601
2021 Q3	–	Sell	-3	Closed	-$255K	–	7315
2021 Q2	$262K	Buy	3 +1	+50%	+$97.3K	﹤0.01%	5838
2021 Q1	$195K	Hold	2	–	–	﹤0.01%	5506
2020 Q4	$552K	Sell	2 -1	-33%	-$277K	﹤0.01%	4120
2020 Q3	$834	Buy	+3	New	+$1.01M	﹤0.01%	3257

Other funds holding WINT

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Gradient Investments Arden Hills, Minnesota $7.25B AUM 20.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Israel Englander's WINT Position: Q1 2023 in Review

Israel Englander sold out of Windtree Therapeutics (WINT) in Q1 2023, closing a stake of 2 shares — an estimated $14K sold.

Israel Englander first reported a position in WINT in Q3 2020 and held it in 6 quarters. The position peaked at $552K in Q4 2020. 2 funds tracked by Wall St. Rank hold WINT as of Q1 2023.

Israel Englander reported no remaining Windtree Therapeutics position as of Q1 2023 after selling out during the quarter.
Israel Englander sold 2 Windtree Therapeutics shares in Q1 2023, an estimated $14K.
Israel Englander first reported a position in Windtree Therapeutics in Q3 2020 and held it in 6 quarters.
Israel Englander's Windtree Therapeutics position peaked at $552K in Q4 2020.
2 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q1 2023.

Based on Millennium Management's 13F filing for Q1 2023, filed 15 May 2023.